Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-U3434
Vaginitis Treatment Drug Market is poised to value USD 4080 million by 2028 end at a CAGR of 5.2% during the forecast period 2022 to 2028. Vaginitis causes discharge, itchiness, and pain in the vaginal area. It is most commonly caused by a change in the balance of vaginal flora or an infection. As well as low estrogen levels after menopause, there are some skin conditions that can cause vaginitis. As vaginal infection can be caused by a variety of bacteria and circumstances, treatment depends on the exact cause. It is the most common kind of vaginitis to be caused by bacteria, fungal vaginitis (yeast infection), and trichomoniasis. The treatment of vaginal dryness can be administered in a variety of ways. It is estimated that nearly half of the female population suffers from bacterial vaginosis (BV) without having any symptoms. It has been found that even when asymptomatic, bacterial vaginosis is linked to a high prevalence of pelvic inflammatory illness and endometritis. Since asymptomatic vaginosis makes detection and prevention difficult, the population has little chance of detecting the infection early on. It is predicted that asymptomatic vaginitis will impede the demand for antibiotics and antifungal medicines. It's important to note that if vaginitis isn't treated, it can lead to miscarriages, pre-term births, and, most importantly, an increased chance of contracting HIV. Aside from chlamydia, gonorrhea, and papillomavirus, other STDs associated with vaginitis include chlamydia and gonorrhea. There is also the possibility of infertility occurring at any time. There is a need for treatment for vaginitis based on the aforementioned facts. In addition to OTC drugs, the market for vaginitis treatment drugs also includes prescription medications. "Vaginitis bacteria transplants" are a novel approach to treating vaginitis. As a result, the vaginitis treatment pharmaceuticals market is likely to become more innovative in the coming years. FutureWise Market Research has instantiated a report that provides an intricate analysis of Vaginitis Treatment Drug Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Vaginitis Treatment Drug Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Vaginitis Treatment Drug Market: • Abbott Laboratories • Baxter International Inc. • B. Braun Melsungen AG • Allergan AG • Johnson & Johnson • Prestige Consumer Healthcare, Inc. • Sanofi SA • Merck & Co Inc. • Aurobindo Pharma Limited • Mylan NV • Sun Pharmaceutical Industries Limited • Pfizer Inc. • Teva Pharmaceutical Industries Ltd • Bayer AG • Dr. Reddy's Laboratories Ltd • Novartis International AG • Cipla Ltd. • Bausch & Lomb Incorporated • Galderma S.A. • Bristol Myers Squibb Company • Perrigo Company plc. • Lupin Pharmaceuticals, Inc. • Glenmark Pharmaceuticals Inc. • Eurofins Scientific SE • Apotex Inc. (Note: The list of the major players will be updated with the latest market scenario and trends) Vaginitis Treatment Drug Market Segmentation: By Drug Type • Nitroimidazole Compound • Lincosamide Antibiotics • Triazoles • Imidazoles By Indication • Bacterial Vaginitis • Fungal Vaginitis (Yeast Infection) • Trichomoniasis By Route of Administration • Oral • Cutaneous • Vaginal By Schedule of Drug • Prescription Drugs (Rx) • Over-the-counter Drugs (OTC) By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Drug Stores • Mail Order Pharmacies By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Vaginitis Treatment Drug Market Sample Video: Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Vaginitis Treatment Drug Market By Drug Type, By Indication, By Route of Administration, By Schedule of Drug, By Distribution Channel and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Vaginitis causes discharge, itchiness, and pain in the vaginal area. It is most commonly caused by a change in the balance of vaginal flora or an infection. As well as low estrogen levels after menopause, there are some skin conditions that can cause vaginitis. As vaginal infection can be caused by a variety of bacteria and circumstances, treatment depends on the exact cause. It is the most common kind of vaginitis to be caused by bacteria, fungal vaginitis (yeast infection), and trichomoniasis. The treatment of vaginal dryness can be administered in a variety of ways. It is estimated that nearly half of the female population suffers from bacterial vaginosis (BV) without having any symptoms. It has been found that even when asymptomatic, bacterial vaginosis is linked to a high prevalence of pelvic inflammatory illness and endometritis. Since asymptomatic vaginosis makes detection and prevention difficult, the population has little chance of detecting the infection early on. It is predicted that asymptomatic vaginitis will impede the demand for antibiotics and antifungal medicines. It's important to note that if vaginitis isn't treated, it can lead to miscarriages, pre-term births, and, most importantly, an increased chance of contracting HIV. Aside from chlamydia, gonorrhea, and papillomavirus, other STDs associated with vaginitis include chlamydia and gonorrhea. There is also the possibility of infertility occurring at any time. There is a need for treatment for vaginitis based on the aforementioned facts. In addition to OTC drugs, the market for vaginitis treatment drugs also includes prescription medications. "Vaginitis bacteria transplants" are a novel approach to treating vaginitis. As a result, the vaginitis treatment pharmaceuticals market is likely to become more innovative in the coming years.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Vaginitis Treatment Drug Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Vaginitis Treatment Drug Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Vaginitis Treatment Drug Market: • Abbott Laboratories • Baxter International Inc. • B. Braun Melsungen AG • Allergan AG • Johnson & Johnson • Prestige Consumer Healthcare, Inc. • Sanofi SA • Merck & Co Inc. • Aurobindo Pharma Limited • Mylan NV • Sun Pharmaceutical Industries Limited • Pfizer Inc. • Teva Pharmaceutical Industries Ltd • Bayer AG • Dr. Reddy's Laboratories Ltd • Novartis International AG • Cipla Ltd. • Bausch & Lomb Incorporated • Galderma S.A. • Bristol Myers Squibb Company • Perrigo Company plc. • Lupin Pharmaceuticals, Inc. • Glenmark Pharmaceuticals Inc. • Eurofins Scientific SE • Apotex Inc. (Note: The list of the major players will be updated with the latest market scenario and trends)
Vaginitis Treatment Drug Market Segmentation: By Drug Type • Nitroimidazole Compound • Lincosamide Antibiotics • Triazoles • Imidazoles By Indication • Bacterial Vaginitis • Fungal Vaginitis (Yeast Infection) • Trichomoniasis By Route of Administration • Oral • Cutaneous • Vaginal By Schedule of Drug • Prescription Drugs (Rx) • Over-the-counter Drugs (OTC) By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Drug Stores • Mail Order Pharmacies By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Vaginitis Treatment Drug Market Sample Video:
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Vaginitis Treatment Drug Market By Drug Type, By Indication, By Route of Administration, By Schedule of Drug, By Distribution Channel and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Vaginitis Treatment Drug Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Vaginitis Treatment Drug Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Vaginitis Treatment Drug Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Vaginitis Treatment Drug Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Nitroimidazole Compound 7.2. Lincosamide Antibiotics 7.3. Triazoles 7.4. Imidazoles 8. Vaginitis Treatment Drug Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1.Bacterial Vaginitis 8.2.Fungal Vaginitis (Yeast Infection) 8.3.Trichomoniasis 9. Vaginitis Treatment Drug Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Oral 9.2. Cutaneous 9.3. Vaginal 10. Vaginitis Treatment Drug Market, By Schedule of Drug Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Prescription Drugs (Rx) 10.2. Over-the-counter Drugs (OTC) 11. Vaginitis Treatment Drug Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Hospital Pharmacies 11.1. Retail Pharmacies 11.1. Drug Stores 11.1. Mail Order Pharmacies 12. North America Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028 15. Asia Pacific Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Abbott Laboratories 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Baxter International Inc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. B. Braun Melsungen AG 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Allergan AG 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5 Johnson & Johnson 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6 Prestige Consumer Healthcare, Inc. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Sanofi SA 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Merck & Co Inc. 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Aurobindo Pharma Limited 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. Mylan NV 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Sun Pharmaceutical Industries Limited 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Pfizer Inc. 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Teva Pharmaceutical Industries Ltd 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. Bayer AG 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15 Dr. Reddy's Laboratories Ltd 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16 Novartis International AG 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. Cipla Ltd. 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. Bausch & Lomb Incorporated 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19. Galderma S.A. 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20. Bristol Myers Squibb Company 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 18.21. Perrigo Company plc. 18.21.1. Company Overview 18.21.2. Product Portfolio 18.21.3. SWOT Analysis 18.21.4. Financial Overview 18.21.5. Strategic Overview 18.22. Lupin Pharmaceuticals, Inc. 18.22.1. Company Overview 18.22.2. Product Portfolio 18.22.3. SWOT Analysis 18.22.4. Financial Overview 18.22.5. Strategic Overview 18.23. Glenmark Pharmaceuticals Inc. 18.23.1. Company Overview 18.23.2. Product Portfolio 18.23.3. SWOT Analysis 18.23.4. Financial Overview 18.23.5. Strategic Overview 18.24. Eurofins Scientific SE 18.24.1. Company Overview 18.24.2. Product Portfolio 18.24.3. SWOT Analysis 18.24.4. Financial Overview 18.24.5. Strategic Overview 18.25 Apotex Inc. 18.25.1. Company Overview 18.25.2. Product Portfolio 18.25.3. SWOT Analysis 18.25.4. Financial Overview 18.25.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Vaginitis Treatment Drug Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Vaginitis Treatment Drug Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Vaginitis Treatment Drug Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Vaginitis Treatment Drug Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Nitroimidazole Compound 7.2. Lincosamide Antibiotics 7.3. Triazoles 7.4. Imidazoles
8. Vaginitis Treatment Drug Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million) 8.1.Bacterial Vaginitis 8.2.Fungal Vaginitis (Yeast Infection) 8.3.Trichomoniasis
9. Vaginitis Treatment Drug Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Oral 9.2. Cutaneous 9.3. Vaginal
10. Vaginitis Treatment Drug Market, By Schedule of Drug Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Prescription Drugs (Rx) 10.2. Over-the-counter Drugs (OTC)
11. Vaginitis Treatment Drug Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Hospital Pharmacies 11.1. Retail Pharmacies 11.1. Drug Stores 11.1. Mail Order Pharmacies
12. North America Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028
15. Asia Pacific Vaginitis Treatment Drug Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix
18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Abbott Laboratories 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Baxter International Inc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. B. Braun Melsungen AG 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Allergan AG 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5 Johnson & Johnson 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6 Prestige Consumer Healthcare, Inc. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Sanofi SA 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Merck & Co Inc. 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Aurobindo Pharma Limited 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. Mylan NV 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. Sun Pharmaceutical Industries Limited 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. Pfizer Inc. 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Teva Pharmaceutical Industries Ltd 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. Bayer AG 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15 Dr. Reddy's Laboratories Ltd 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16 Novartis International AG 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. Cipla Ltd. 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. Bausch & Lomb Incorporated 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19. Galderma S.A. 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20. Bristol Myers Squibb Company 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 18.21. Perrigo Company plc. 18.21.1. Company Overview 18.21.2. Product Portfolio 18.21.3. SWOT Analysis 18.21.4. Financial Overview 18.21.5. Strategic Overview 18.22. Lupin Pharmaceuticals, Inc. 18.22.1. Company Overview 18.22.2. Product Portfolio 18.22.3. SWOT Analysis 18.22.4. Financial Overview 18.22.5. Strategic Overview 18.23. Glenmark Pharmaceuticals Inc. 18.23.1. Company Overview 18.23.2. Product Portfolio 18.23.3. SWOT Analysis 18.23.4. Financial Overview 18.23.5. Strategic Overview 18.24. Eurofins Scientific SE 18.24.1. Company Overview 18.24.2. Product Portfolio 18.24.3. SWOT Analysis 18.24.4. Financial Overview 18.24.5. Strategic Overview 18.25 Apotex Inc. 18.25.1. Company Overview 18.25.2. Product Portfolio 18.25.3. SWOT Analysis 18.25.4. Financial Overview 18.25.5. Strategic Overview
19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations
20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics